CELYAD SA/ADR (NASDAQ:CYAD)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $20.58 and last traded at $20.88, with a volume of 682 shares trading hands. The stock had previously closed at $24.75.

Several equities analysts have issued reports on CYAD shares. William Blair restated a “buy” rating on shares of CELYAD SA/ADR in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of CELYAD SA/ADR in a research report on Wednesday, November 21st. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Thursday, November 15th. Finally, Piper Jaffray Companies decreased their price objective on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research report on Monday, November 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $44.20.

The stock has a market capitalization of $210.28 million, a price-to-earnings ratio of -6.61 and a beta of 1.35.

Several institutional investors and hedge funds have recently bought and sold shares of CYAD. Victory Capital Management Inc. increased its position in shares of CELYAD SA/ADR by 41.9% during the second quarter. Victory Capital Management Inc. now owns 604,002 shares of the company’s stock worth $18,717,000 after buying an additional 178,380 shares during the period. Stanley Laman Group Ltd. acquired a new stake in shares of CELYAD SA/ADR during the second quarter worth $1,145,000. Millennium Management LLC acquired a new stake in shares of CELYAD SA/ADR during the second quarter worth $582,000. Finally, Wells Fargo & Company MN increased its position in shares of CELYAD SA/ADR by 1,109.0% during the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after buying an additional 5,545 shares during the period. Institutional investors own 7.45% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “CELYAD SA/ADR (CYAD) Reaches New 12-Month Low at $20.58” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.watchlistnews.com/celyad-sa-adr-cyad-reaches-new-12-month-low-at-20-58/2671005.html.

CELYAD SA/ADR Company Profile (NASDAQ:CYAD)

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Featured Story: What kind of dividend yield to CEF’s pay?

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.